Treatment of (ir-allyl)palladium complexes such as 6 and 9 with Pd(PPh3)4 leads to rapid isomerization at -15 °C in tetrahydrofuran and other solvents. At 0 °C and in the presence of more than 2 equiv of triphenylphosphine per palladium, the phosphine attacks the ir-allyl group to give allylic phosphonium salts 7 with concomitant formation of a palladium(0)-phosphine complex, and isomerization of 6 is observed. Attack by PPh3 on 6 was shown to be stereospecific and to proceed with inversion. Studies of the Pd(0)-catalyzed substitution of le (X = OAc) with several different nucleophiles support the hypothesis that

Excess mineralocorticoid receptor (MR) activation promotes target organ dysfunction, vascular injury and fibrosis. MR antagonists like eplerenone are used for treating heart failure, but their use is limited due to the compound class-inherent hyperkalemia risk. Here we present evidence that AZD9977, a first-in-class MR modulator shows cardio-renal protection despite a mechanism-based reduced liability to cause hyperkalemia. AZD9977 in vitro potency and binding mode to MR were characterized using reporter gene, binding, cofactor recruitment assays and X-ray crystallopgraphy. Organ protection was studied in uni-nephrectomised db/db mice and uni-nephrectomised rats administered aldosterone and high salt. Acute effects of single compound doses on urinary electrolyte excretion were tested in rats on a low salt diet. AZD9977 and eplerenone showed similar human MR in vitro potencies. Unlike eplerenone, AZD9977 is a partial MR antagonist due to its unique interaction pattern with MR, which results in a distinct recruitment of co-factor peptides when compared to eplerenone. AZD9977 dose dependently reduced albuminuria and improved kidney histopathology similar to eplerenone in db/db uni-nephrectomised mice and uni-nephrectomised rats. In acute testing, AZD9977 did not affect urinary Na+/K+ ratio, while eplerenone increased the Na+/K+ ratio dose dependently. AZD9977 is a selective MR modulator, retaining organ protection without acute effect on urinary electrolyte excretion. This predicts a reduced hyperkalemia risk and AZD9977 therefore has the potential to deliver a safe, efficacious treatment to patients prone to hyperkalemia.

No abstract

No abstract

No abstract

5-Lipoxygenase activating protein (FLAP) inhibitors attenuate 5-lipoxygenase pathway activity and reduce the production of proinflammatory and vasoactive leukotrienes. As such, they are hypothesized to have therapeutic benefit for the treatment of diseases that involve chronic inflammation including coronary artery disease. Herein, we disclose the medicinal chemistry discovery and the early clinical development of the FLAP inhibitor AZD5718 (12). Multiparameter optimization included securing adequate potency in human whole blood, navigation away from Ames mutagenic amine fragments while balancing metabolic stability and PK properties allowing for clinically relevant exposures after oral dosing. The superior safety profile of AZD5718 compared to earlier frontrunner compounds allowed us to perform a phase 1 clinical study in which AZD5718 demonstrated a dose dependent and greater than 90% suppression of leukotriene production over 24 h. Currently, AZD5718 is evaluated in a phase 2a study for treatment of coronary artery disease.

The mechanism-based risk for hyperkalemia has limited the use of mineralocorticoid receptor antagonists (MRAs) like eplerenone in cardio-renal diseases. Here, we describe the structure and property-driven lead generation and optimization, which resulted in identification of MR modulators (S)-1 and (S)-33. Both compounds were partial MRAs but still demonstrated equally efficacious organ protection as eplerenone after 4 weeks of treatment in uni-nephrectomized rats on high-salt diet and aldosterone infusion. Importantly, and in sharp contrast to eplerenone, this was achieved without substantial changes to the urine Na + /K + ratio after acute treatment in rat, which predicts a reduced risk for hyperkalemia. This work led to selection of (S)-1 (AZD9977) as the clinical candidate for treating MR-mediated cardio-renal diseases, including chronic kidney disease and heart failure. On the basis of our findings, we propose an empirical model for prediction of compounds with low risk of affecting the urinary Na + /K + ratio in vivo.

The mechanism of the loss of stereospecificity in palladium‐catalyzed nucleophilic substitution of allylic substrates has been investigated. Eight substrates (cis and trans isomers of 1a‐d) and two nucleophiles (Et2NH and NaCH(SO2Ph)2) were studied. In the animation reactions two pathways are responsible for the formation of anomalous inversion product, viz., isomerization of the starting material (path B, Scheme 2) and isomerization of the π‐allyl intermediate via displacement of palladium by Pd(0) (path C, Scheme 2), the latter of which predominates. In the alkylation the results indicate that loss of stereospecificity is caused only by path C. The use of a more reactive substrate increased the stereospecificity of the reaction and suppressed the isomerization pathway. An analysis of the kinetics is consistent with the hypothesis that path C is the major pathway for the stereochemical loss.